Dr Phillip J. Koo provides his thoughts on the use of advanced PET imaging in prostate cancer


Introducing the RADAR studies

Dr Phillip J. Koo provides his thoughts on the use of advanced PET imaging in prostate cancer. He covers when to use these tools by examining the published data, specifically the RADAR 1 and 3 studies. The RADAR (radiographic assessments for detection of advanced recurrence) group, are a team of experts, including Dr Koo, who have published articles pertinent to prostate cancer imaging. The initial paper of RADAR 1 reviewed imaging guidelines with associated clinical validation studies for metastatic prostate cancer. It provided recommendations for clinical practice to improve early detection of metastatic disease. RADAR III focuses on updates regarding next generation imaging for improved guidance.

Important findings for imaging metastatic prostate cancer

In this video and associated slides, Dr Koo details the RADAR 1 and 3 recommendations, comparing conventional imaging to advanced PET imaging for detection of metastatic disease in prostate cancer. Prostate cancer PET detection rates as a function of PSA in patients with biochemical recurrence are addressed. The suitability of radiotracers for next generation imaging is discussed, and how to approach different patient groups. Lastly, what test to use based on availability, accounting for location and coverage by MEDICARE. View the video and slides provided as part of our educational resources and practical guidance for medical oncologists and urologists.

Phillip J. Koo, MD is the Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine. Dr Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian, radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System, and fellowship at the Harvard Medical School Joint Program in Nuclear Medicine. He is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine. Dr Koo is an active member of multiple societies and serves on the Scientific Program Committee for the Radiological Society of North America, Nuclear Radiology Certifying Exam Committee for the ABR, and is the Chair of the Quality and Evidence Committee for the Society of Nuclear Medicine and Molecular Imaging (SNMMI).  He is also Chair of the Prostate Cancer Working Group at the SNMMI and was a member of the RADAR I and II working groups. Dr Koo has published on various topics related to radiology and nuclear medicine in multiple journals such as Radiology, Radiographics, European Journal of Nuclear Medicine and Molecular Imaging, Urology, and Journal of the American College of Radiology.  

Dr Phillip Koo has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Bayer, Blue Earth, Janssen, Lantheus, Merck and Novartis. 

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

podcast Podcast

Episode

4

of 4

episode
Oncology 
HCC podcast series part 4: Intermediate HCC – the evolving role of IO

Integrating multimodal approaches with multidisciplinary care

Experts
Dr Edward Kim, Dr Nina Sanford, Dr Mark Yarchoan, Oncology Brothers (Moderators)
Endorsed by
Blue Faery plus Global Liver Institute DiCE
ELPA
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.
video Video
Oncology 
The evolving role of liquid biopsy in HR+/HER2- metastatic breast cancer

Exploring the impact of liquid biopsy in advanced breast cancer

Experts
Prof. Frédérique Penault-Llorca, Dr Aditya Bardia
Endorsed by
ISLB
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from Thermo Fisher Scientific.
animated-video Animated Video
Oncology Obstetrics and Gynecology 
Current treatment options in advanced/recurrent endometrial cancer

Exploring the impact of molecular subtypes 

Experts
Prof. Christian Marth
  • download Downloadable
    Resources
  • clock 7 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of or speakers involved in this programme.
podcast Podcast

Episode

3

of 4

episode
Oncology 
HCC podcast series part 3: Intermediate HCC – treatment options and strategies

Expert insights on systemic, loco-regional, and multimodal therapies

Experts
Dr Maria Reig, Dr Emil I Cohen, Oncology Brothers (Moderators)
Endorsed by
DiCE Blue Faery plus Global Liver Institute
ELPA
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from Bayer.
video Video
Oncology 
Recent advances in precision oncology and future implications

Two emerging and two established targets

Experts
Prof. David Hong
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Survey on the evolving role of the oncology nurse in the USA

Announcing the publication of survey results 

Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo
  • download Downloadable
    Resources
  • clock 10 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.